Summary of Belite Bio (BLTE) Q2 2026 Earnings Call

1Key Financial Results and Metrics

R&D Expenses:: $18.2 million, up from $11 million in Q2 2025, primarily due to a royalty payment related to a milestone achievement.

Non-GAAP R&D Expenses:: $17.2 million, compared to $8.6 million in Q2 2025.

SG&A Expenses:: $16.7 million, up from $6.5 million in the same period last year, driven by increased professional service fees and team expansion.

Non-GAAP SG&A Expenses:: $10.9 million, compared to $1.3 million in Q2 2025.

GAAP Net Loss:: $28.4 million, compared to $16.3 million in Q2 2025.

Non-GAAP Net Loss:: $21.6 million, compared to $8.7 million in Q2 2025.

Cash Position:: $780 million in cash, cash equivalents, and U.S. Treasury bills, providing a strong financial runway for future operations.

2Strategic Updates and Business Highlights

FDA Acceptance:: The FDA has accepted the new drug application (NDA) for tinlarebant for Stargardt disease with priority review, setting a PDUFA date of February 12, 2027.

Clinical Data Presentation:: Phase 3 Dragon study results were presented at four medical conferences, showing promising data on the drug's efficacy in halting retinal degeneration.

Pediatric Study Plans:: Initiating a pediatric study (PIP) for ages 3 to 11 to inform regulatory processes for younger patients.

Geographic Expansion:: Plans for a European filing post-U.S. approval, aligning with FDA communications.

3Forward Guidance and Outlook

Regulatory Focus:: The primary focus remains on securing FDA approval for tinlarebant, with expectations for a concurrent submission in Japan approximately three months after U.S. approval.

Priority Review Voucher:: If approved, the company expects to receive a priority review voucher due to the rare pediatric disease designation, although plans for its use (sale or retention) are not yet determined.

4Bad News, Challenges, or Points of Concern

Increased Losses:: The company reported a significant increase in net losses compared to the previous year, raising concerns about the sustainability of current spending levels.

Regulatory Uncertainty:: While the NDA has been accepted, there is no confirmation on the specifics of the drug label, particularly regarding age inclusivity, which could impact market potential.

Potential for AdCom:: There is uncertainty regarding whether the FDA will require an Advisory Committee meeting (AdCom), which could delay the approval process.

5Notable Q&A Insights

Dragon 2 Study:: The Dragon 2 study is primarily for Japan and is not expected to contribute to the U.S. NDA process.

Compliance Rates:: Over 90% of patients in the Stargardt study have adhered to the dosing regimen after 24 months, indicating strong treatment compliance.

Royalty Payment Confidentiality:: The specific amount of the royalty payment related to the Phase 3 study completion remains confidential as requested by the partner.

Interim Analysis for GA Trial:: The interim analysis for the geographic atrophy trial is expected to occur in Q1 2027, likely after the FDA's PDUFA date. This summary encapsulates the key points from the earnings call, providing a clear overview of Belite Bio's financial performance, strategic direction, and potential challenges ahead.